No Detail Found!

Prognostic Signi cance of CD4+ Tumour In ltrating Lymphocytes in Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors Therapy

Author(s)
Qi-Ming Zheng Department of Thoracic Surgery, Jinan Central Hospital, Shandong University, Jinan, China; Department of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
Yuan-Yuan Li Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, China
Ye-Peng Wang Department of Neurosurgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
Guo-Xiang Li Department of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
Zhi-Gang Sun Department of Thoracic Surgery, Jinan Central Hospital, Shandong University, Jinan, China; Department of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
Min Zhang Department of Dermatology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
Abstract
CD4+ tumour in ltrating lymphocytes (TILs) have been found to produce a marked e ect in anti-tumour immunity. In the present study, the authors explored the predictive value of CD4+ TILs in patients with non-small cell lung cancer (NSCLC) receiving PD-1/PD-L1 inhibitors therapy. The authors searched Cochrane, Embase, PubMed, and the Web of Science with a November 2023 deadline. This study followed the requirements of the preferred reporting items for systematic reviews and meta-analyses (PRISMA). The data were analysed by Stata MP17.0 software. Endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). In total, 13 studies ultimately met the inclusion criteria. Findings showed high levels of CD4+ TILs in tumour tissue were correlated with better ORR (OR = 1.78, 95% CI: 1.15-2.76, p = 0.010) in NSCLC patients, rather than PFS (HR = 0.82, 95% CI: 0.65-1.05, p = 0.11) and OS (HR = 0.86, 95% CI: 0.69-1.09, p = 0.217). In addition, high levels of peripheral blood CD4+ T cells correlated with better PFS (HR = 0.66, 95% CI: 0.46-0.94, p = 0.02), rather than OS (HR = 0.90, 95% CI: 0.69-1.19, p = 0.461). The results demonstrated that high CD4+ TILs in tumour tissue can predict better ORR for NSCLC patients receiving PD-1/PD-L1 inhibitors, and high peripheral blood CD4+ T cells can predict better PFS.
Publication Details
Page(s) 341-350
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 35, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
prognosis, Non-small Cell Lung Cancer, Peripheral blood, Immune checkpoint inhibitors, CD4-positive T-lymphocytes, Tumour-in ltrating
References
Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A .2020 .GLOBOCAN esti-. Global cancer statistics, : .
Speiser DE,Ho PC,Verdeil G .2016 .Regulatory circuits of T cell function in cancer. Nat Rev Immunol, 80(10) : 599-611.
Mittal D,Gubin MM,Schreiber RD,Smyth MJ RD .2014 .New insights into cancer immunoediting and its three component phases Elimination, equilibrium and escape. Curr Opin Immunol, 01 : 16-25.
Li F,Li C,Cai X,Xie Z,Zhou L,Cheng B .2021 .The association between CD8+ tumour-in ltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. EClinicalMedicine, 101134 : 101134.
Zheng QM,Li YY,Wang YP,Li GX,Zhao MM,Sun ZG .2023 .Association between CD8+ tumour-in ltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis. Expert Rev Anticancer Ther, 2208351(6) : 643-59.
Moher D,Shamseer L,Clarke M,Ghersi D,Liberati A,Petticrew M .2015 .Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 10(1) : 1-9.
Haddaway NR,Page MJ,Pritchard CC,McGuinness LA .2022 .PRISMA2020: An R package and shiny app for producing PRISMA 2020-compliant ow diagrams, with interactivity for optimised digital transparency. Campbell Syst Rev, 10(2) : 1230.
Wells G,Shea B,O'Connell D,Peterson J,Welch V,Losos M .2021 .Newcastle-ottawa quality assessment scale cohort studies. (accessed on 28 January, : .
Tierney JF,Stewart LA,Ghersi D,Burdett S,Sydes MR .2007 .Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 10 : 1745.
Du X,Wen S,Shi R,Xia J,Wang R,Zhang Y .2023 .Peripheral blood lymphocytes di erentiation patterns in responses / outcomes to immune checkpoint blockade therapies in nonsmall cell lung cancer: A retrospective study. BMC Cancer, 10(1) : 83.
Lieskovan SH,Lisberg A,Zaretsky JM,Grogan TR,Rizvi H,Wells DK .2019 .Tumour characteristics associated with bene t from pembrolizumab in advanced non-small cell lung cancer. Clin Cancer Res, 18(16) : 1078-0432.
Kaira K,Yamaguchi O,Kawasaki T,Hashimoto K,Miura Y,Shiono A .2023 .Prognostic signi cance of tumour in ltrating lymphocytes on rst-line pembrolizumab e cacy in advanced non-small cell lung cancer. Discov Oncol, 10(1) : .
Koh YW,Han JH,Haam S,Lee HW .2022 .Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumour-in ltrating immune cells in non-small cell carcinoma. Front Oncol, 996634 : 996634.
Li P,Qin P,Fu X,Zhang G,Yan X,Zhang M .2021 .Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor. Ann Palliat Med, 10(3) : 3039-49.
de Rodas ML,Nagineni V,Ravi A,Datar IJ,Kenudson MM,Corredor G .2022 .Role of tumour in ltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. J Immunother Cancer, 10(6) : .
Mazzaschi G,Minari R,Zecca A,Cavazzoni A,Ferri V,Mori C .2020 .Soluble PD-L1 and circulating CD8+PD-1+ and NK cells enclose a prognostic and predictive immune e ector score in immunotherapy treated NSCLC patients. Lung Cancer, 07 : 1-11.
Niemeijer AN,Sahba S,Smit EF,Witte BIL,de Langen AJ,Thunnissen E. .2020 .Association of tumour and stroma PD-1, PDL1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy. Br J Cancer, 10(3) : 392-402.
Ottonello S,Genova C,Cossu I,Fontana V,Rijavec E,Rossi G .2020 .Association between response to nivolumab treatment and peripheral blood lymphocyte subsets in patients with non-small cell lung cancer. Front Immunol, 00125 : 125.
Uryvaev A,Passhak M,Hershkovits D,Sabo E,Sela GB .2018 .The role of tumour-in ltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol, 10(3) : 25.
Wu K,Xia B,Zhang J,Li X,Yang S,Zhang M .2022 .Positive correlation of peripheral CD8+ T lymphocytes with immunerelated adverse events and combinational prognostic value in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors. Cancers, 10(15) : 3568.
Yan Y,Wang X,Liu C,Jia J .2022 .Association of lymphocyte subsets with e cacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: A retrospective study. BMC Pulm Med, 10(1) : 166.
Zugazagoitia J,Gupta S,Liu Y,Fuhrman K,Gettinger S,Herbst RS .2020 .Biomarkers associated with bene cial PD-1 checkpoint blockade in non-small cell lung cancer (NSCLC) identi ed using high-plex digital spatial pro lCinlign. Cancer Res, 20(16) : 1078-0432.
Liu B,Song Y,Liu D. .2017 .Recent development in clinical applicat i o n s o f P D - 1 a n d P D - L 1 a n t i b o d i e s f o r c a n c e r immunotherapy. J Hematol Oncol, 10(1) : 174.
Spranger S,Spaapen RM,Zha Y,Williams J,Meng Y,Ha TT .2013 .Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumour microenvironment is driven by CD8(+) T cells. Sci Transl Med, 10(200) : .
Pardoll DM .2012 .The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 10(4) : 252-64.
Alspach E,Lussier DM,Miceli AP,Kizhvatov I,DuPage M,Luoma AM .2019 .MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature, 10(7780) : 696-701.
Pyke RM,Thompson WK,Salem RM,Burgada JF,Zanetti M,Carter H M .2018 .Evolutionary pressure against MHC class II binding cancer mutations. Cell, 08(2) : 416-28.
Ahrends T,Spanjaard A,Pilzecker B,Babala N,Bovens A,Xiao Y .2017 .CD4+ T cell help confers a cytotoxic t cell e ector program including coinhibitory receptor downregulation and Increased tissue invasiveness. Immunity, 10(5) : 848-61.
Zander R,Schauder D,Xin G,Nguyen C,Wu X,Zajac A .2019 .CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer. Immunity, 10(6) : 1028-42.
Togashi Y,Shitara K,Nishikawa H K .2019 .Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol, 10(6) : 356-71.
Borst J,Ahrends T,Babala N,Melief CJM,Kastenmuller W. .2018 .CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol, 10(10) : 635-47.
Balanca CC,Salvioni A,Scarlata CM,Michelas M,Gomez CM,Roca CG .2021 .PD-1 blockade restores helper activity of tumour-in ltrating, exhausted PD-1hiCD39+ CD4 T cells. JCI Insight, 142513(2) : .
Bassez A,Vos H,Van Dyck L,Floris G,Arijs I,Desmedt C .2021 .A single-cell map of intratumoural changes during antiPD1 treatment of patients with breast cancer. Nat Med, 10(5) : 820-32.
Li K,Tandurella JA,Gai J,Zhu Q,Lim SJ,Thomas DL .2022 .Multi-omic analyses of changes in the tumour microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell, 10(11) : 1374-91.
An HJ,Chon HJ,Kim C .2021 .Peripheral blood-based biomarkers for immune checkpoint inhibitors. Int J Mol Sci, 10(17) : 9414.
Zhang F,Bai H,Gao R,Fei K,Duan J .2020 .Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer. Cancer Immunol Immunother, 10(12) : 2599-611.
Arasanz H,Zuazo M,Bocanegra A,Gato M,Aguillo MM,Morilla I .2020 .Early detection of hyperprogressive disease in non-small cell lung cancer by monitoring of systemic T cell dynamics. Cancers, 10(2) : 344.
Xia L,Wang H,Sun M,Yang Y,Yao C,He S .2021 .Peripheral CD4+ T cell signatures in predicting the responses to antiPD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. Sci China Life Sci, 10(10) : 1590-601.
Fundytus A,Booth CM,Tannock IF .2021 .How low can you go? PDL1 expression as a biomarker in trials of cancer immunotherapy. Ann Oncol, 03(7) : 833-6.
0

Citations

0

Downloads

108

Views